Zhengye Biotechnology Holding Ltd (ZYBT): Operating Cash Flow

Annual figures by period end, from SEC filings.

13.33M CNY
Year ended 2025-12-31
-8.4%
3-year compound annual growth
48.18M CNY2022-12-31: 17.34M CNY2023-12-31: 48.18M CNY2024-12-31: 41.05M CNY2025-12-31: 13.33M CNY13.33M CNY
2022-12-31 Operating Cash Flow (CNY) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-3113.33M CNY-67.5%2026-04-28, From 2025-01-01
2024-12-3141.05M CNY-14.8%2026-04-28, From 2024-01-01
2023-12-3148.18M CNY+178.0%2026-04-28, From 2023-01-01
2022-12-3117.34M CNYn/a2025-07-03, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Zhengye Biotechnology Holding Ltd (ZYBT)2025-12-3113.33M CNY-67.5%
Yatsen Holding Ltd (YSG)2025-12-31-94.66M CNYn/m

Compare ZYBT, YSG side by side · Screen every company in Pharmaceutical Preparations ↗